公开(公告)号：US11945861B2

公开(公告)日：2024-04-02

申请号：US17154350

申请日：2021-01-21

申请人： IMMUNOQURE AG

发明人： Syeda F. Y. Haque ,  Adrian Hayday ,  Kai Kisand ,  Kai Krohn ,  Annalisa Macagno ,  Steffen Meyer ,  Paert Peterson ,  Mike Rothe ,  Philip Vlaicu ,  Martin Woodward

IPC分类号： C07K16/24 ,  A61K47/68 ,  G01N33/564 ,  G01N33/68

CPC分类号： C07K16/249 ,  A61K47/6845 ,  G01N33/564 ,  G01N33/6866 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/56

摘要： Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-α antibodies as well as IFN-α binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

公开(公告)号：US11858986B2

公开(公告)日：2024-01-02

申请号：US17092998

申请日：2020-11-09

申请人： PFIZER INC. ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Stefano V. Gulla ,  Christine Huard ,  Janet Elizabeth Buhlmann ,  Juan Carlos Almagro ,  Sreekumar R. Kodangattil ,  Steven A. Greenberg ,  Edward Roland Lavallie ,  Eric M. Bennett ,  Lidia Mosyak ,  James Perry Hall ,  Anthony John Coyle

IPC分类号： C07K16/24 ,  A61K39/00

CPC分类号： C07K16/249 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.

公开(公告)号：US20230220093A1

公开(公告)日：2023-07-13

申请号：US18151227

申请日：2023-01-06

申请人： APRILBIO CO., LTD.

发明人： Sang Hoon CHA

IPC分类号： C07K16/28 ,  C07K16/24 ,  C07K16/18

CPC分类号： C07K16/2875 ,  C07K16/249 ,  C07K16/244 ,  C07K16/18 ,  C07K16/241 ,  C07K2317/31 ,  C07K2317/94 ,  C07K2317/92 ,  C07K2317/622 ,  C07K2317/55

摘要： The present disclosure provides multispecific antibodies having increased in vivo sustainability, the multispecific antibodies comprising one or more bioactive effector moieties linked to either or both of an N-terminal and a C-terminal of an antigen binding fragment Fab that binds to human serum albumin.

公开(公告)号：US20180243377A1

公开(公告)日：2018-08-30

申请号：US15869503

申请日：2018-01-12

申请人： Rutgers, The State University of New Jersey

发明人： Sergei V. Kotenko ,  Grant F. Gallagher

IPC分类号： A61K38/21 ,  C07K16/28 ,  A61K38/17 ,  A61K39/395 ,  C07K14/555 ,  C07K14/715 ,  C07K16/24 ,  G01N33/68

CPC分类号： A61K38/21 ,  A61K38/00 ,  A61K38/1793 ,  A61K39/3955 ,  A61K2039/507 ,  C07K14/555 ,  C07K14/7156 ,  C07K16/249 ,  C07K16/2866 ,  C07K2319/00 ,  G01N33/6866 ,  G01N2333/555 ,  G01N2500/02

摘要： A novel IFN-α/ß independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

公开(公告)号：US20170129947A1

公开(公告)日：2017-05-11

申请号：US15270813

申请日：2016-09-20

申请人： Salk Institute for Biological Studies ,  Kolltan Pharmaceuticals, Inc.

发明人： Greg E. Lemke ,  Lawrence C. Fritz ,  Benedikt Vollrath ,  Carla V. Rothlin

IPC分类号： C07K16/18 ,  A61K45/06 ,  A61K39/395

CPC分类号： C07K16/18 ,  A61K9/1275 ,  A61K31/444 ,  A61K38/17 ,  A61K38/1761 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6911 ,  A61K2039/505 ,  C07K16/249 ,  C07K2317/76 ,  C12N2740/16011 ,  C12Q1/025 ,  C12Q1/701 ,  G01N33/56983 ,  G01N2800/24

摘要： The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.

公开(公告)号：US20170107302A1

公开(公告)日：2017-04-20

申请号：US15169852

申请日：2016-06-01

申请人： Ablynx N.V.

发明人： KAREN SILENCE ,  Marc Jozef Lauwereys ,  Torsten Dreier

IPC分类号： C07K16/46 ,  C07K16/36 ,  C07K16/24

CPC分类号： C07K16/468 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/241 ,  C07K16/249 ,  C07K16/2863 ,  C07K16/2875 ,  C07K16/36 ,  C07K16/40 ,  C07K16/42 ,  C07K16/4291 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/626 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

摘要： The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.

公开(公告)号：US20170096481A1

公开(公告)日：2017-04-06

申请号：US15157830

申请日：2016-05-18

申请人： Ablynx N.V.

发明人： KAREN SILENCE ,  Marc Jozef Lauwereys ,  Hans De Haard

IPC分类号： C07K16/24 ,  C07K16/18

CPC分类号： C07K16/241 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/249 ,  C07K16/2863 ,  C07K16/2875 ,  C07K16/36 ,  C07K16/40 ,  C07K16/4291 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/626 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

摘要： The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.

公开(公告)号：US20170051055A1

公开(公告)日：2017-02-23

申请号：US14902409

申请日：2014-07-03

申请人： IMMUNOQURE AG

发明人： Syeda F.Y. HAQUE ,  Adrian HAYDAY ,  Kai KISAND ,  Kai KROHN ,  Annalisa MACAGNO ,  Steffen MEYER ,  Paert PETERSON ,  Mike ROTHE ,  Philip VLAICU ,  Martin WOODWARD

IPC分类号： C07K16/24 ,  G01N33/564 ,  G01N33/68

CPC分类号： C07K16/249 ,  A61K47/6845 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/564 ,  G01N33/6866 ,  G01N2333/56

摘要： Provided are novel IFN-α binding molecules of human origin, particularly human-derived anti-IFN-α antibodies as well as IFN-α binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.

摘要翻译： 提供了人源的新型IFN-α结合分子，特别是人源抗体IFN-α抗体以及IFN-α结合片段，其衍生物和变体。 此外，描述了用于诊断和治疗的药物组合物，试剂盒和方法。

公开(公告)号：US20160280799A1

公开(公告)日：2016-09-29

申请号：US15063961

申请日：2016-03-08

申请人： Ablynx NV.

发明人： MARIE-PAULE LUCIENNE ARMANDA BOUCHE ,  Peter Vanlandschoot ,  Erwin Sablon ,  Erik Depla ,  Stefan De Buck ,  Xavier Saelens ,  Bert Schepens ,  Karen Silence ,  Mark Vaeck ,  Paul M. P. Van Bergen En Henegouwen ,  Hans De Haard

IPC分类号： C07K16/42 ,  C07K16/18 ,  C07K16/28 ,  C07K16/46 ,  C07K16/24 ,  C07K16/40

CPC分类号： C07K16/4291 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/542 ,  A61K2039/544 ,  A61M11/005 ,  A61M15/0065 ,  C07K16/1027 ,  C07K16/18 ,  C07K16/241 ,  C07K16/244 ,  C07K16/249 ,  C07K16/2863 ,  C07K16/2875 ,  C07K16/36 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2319/00 ,  C07K2319/31

摘要： In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.

摘要翻译： 一方面，本发明涉及其中免疫球蛋白单可变结构域（例如纳米抗体）和/或其构建体被吸收在肺组织中的方法。 更具体地，本发明提供了经由肺途径的免疫球蛋白单可变结构域和/或其构建体的全身递送。

公开(公告)号：US20160264685A1

公开(公告)日：2016-09-15

申请号：US15068916

申请日：2016-03-14

申请人： NovImmune SA

发明人： Nicolas Fouque ,  Jean François Depoisier ,  Keith Wilson ,  Judith Vajda ,  Egbert Müller ,  Romain Dabre

IPC分类号： C07K16/46 ,  C07K1/36 ,  C07K1/22 ,  C07K1/16 ,  C07K1/20

CPC分类号： C07K16/468 ,  C07K1/16 ,  C07K1/165 ,  C07K1/20 ,  C07K1/22 ,  C07K1/36 ,  C07K16/00 ,  C07K16/248 ,  C07K16/249 ,  C07K16/2866 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/52

摘要： The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain. This invention in particular relates to the isolation of these bispecific antibodies from mixtures that contain monospecific antibodies having two Kappa light chains or portions thereof and monospecific antibodies having two Lambda light chains or portions thereof. The invention also provides the methods of efficiently purifying these bispecific antibodies.

摘要翻译： 本发明涉及从单特异性抗体的混合物纯化对免疫球蛋白分子的每个结合位点具有不同特异性的双特异性抗体。 双特异性抗体由单个重链和两个不同的轻链组成，一个含有κ恒定结构域，另一个是λ恒定结构域。 本发明特别涉及从包含具有两个κ轻链或其部分的单特异性抗体和具有两个λ轻链或其部分的单特异性抗体的混合物中分离出这些双特异性抗体。 本发明还提供了有效纯化这些双特异性抗体的方法。